Real world evidence of changes in CGRP monoclonal antibody and onabotulinumtoxinA prescription practices at the start of the COVID-19 pandemic: An observational, retrospective study

Headache. 2023 Sep;63(8):1180-1182. doi: 10.1111/head.14585. Epub 2023 Jun 26.

Authors

Leon S Moskatel¹, Anna Graber-Naidich², Zihuai He^{1

2}, Niushen Zhang¹

Affiliations

¹ Department of Neurology and Neurological Sciences, Stanford University, Stanford, California, USA.
² Quantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, California, USA.

PMID: 37358470
DOI: 10.1111/head.14585

No abstract available

Keywords: calcitonin gene-related peptide monoclonal antibodies; coronavirus disease 2019; headache; onabotulinumtoxinA; real world evidence.

Publication types

Observational Study
Letter

MeSH terms

Antibodies, Monoclonal
Botulinum Toxins, Type A* / therapeutic use
COVID-19*
Calcitonin Gene-Related Peptide
Humans
Retrospective Studies

Substances

Antibodies, Monoclonal
Calcitonin Gene-Related Peptide
Botulinum Toxins, Type A